Doctor driven sales are the key Patel - along with insurance based reimbursement, so that the patient doesn’t pay - along with having approval (FDA) to sell into the most lucrative market in the world, who has a massive issue trying to reduce huge healthcare system costs.
Australia was a test market, with the particularly important achievement of the RAMP program which has enabled a US launch a good 9 months ahead of forecast.
Watch this space Patel.....US sales to increase, all while RAP continues to fumble around without FDA approval.
Doctor driven sales are the key Patel - along with insurance...
Add RSH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.4¢ |
Change
0.004(13.3%) |
Mkt cap ! $36.03M | |||
| Open | High | Low | Value | Volume |
| 3.0¢ | 3.4¢ | 3.0¢ | $36.75K | 1.184M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 224180 | 3.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.4¢ | 79999 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
3.4¢ |
Change
0.004 ( 13.3 %) |
||||
| Open | High | Low | Volume | ||
| 3.2¢ | 3.4¢ | 3.2¢ | 71127 | ||
| Last updated 14.52pm 03/05/2024 ? | |||||
| RSH (ASX) Chart |